Seres Therapeutics (MCRB) Misses Q1 EPS by 8c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. HOOD
2. ENPH
3. KIDS
4. BA
5. STX
6. NXPI
7. MANH
8. BKR
9. CSGP
10. SKHY

Go back to Seres Therapeutics (MCRB) Misses Q1 EPS by 8c, Revenues Miss

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

May 4, 2021 7:00 AM EDT

Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021

Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject enrollment target in Q3 2021

Virtual ulcerative colitis microbiome therapeutic investor event to be held June 21, 2021

Conference call at 8:30 a.m. ET today

CAMBRIDGE, Mass.--(BUSINESS... More